COVID-19 May Increase Risk for Adverse Pregnancy Outcomes
COVID-19 is associated with increased risks for preeclampsia, preterm birth, and other adverse pregnancy outcomes.
COVID-19 is associated with increased risks for preeclampsia, preterm birth, and other adverse pregnancy outcomes.
The objective of this study was to evaluate the risks of first-trimester exposure to prescription opioids for major congenital malformations.
Opioid use in early pregnancy is associated with a small increase in risk for cleft palate but no increase in risk for most major congenital malformations.
From 2010 to 2017, there were significant increases in the estimated rates of neonatal abstinence syndrome and maternal opioid-related diagnoses.
Opioid coprescription with psychotropic medications during pregnancy increases a woman’s antepartum hospitalization risk.
The CDC analyzed prescription opioid use during pregnancy via a self-reported survey.
A particular challenge in this population is the effective management of migraine during pregnancy and lactation while minimizing the risk for harm to the fetus.
Prenatal opioid exposure may be associated with poorer cognitive and motor development in children from age 6 months to adolescence.
A particular challenge in this population is the effective management of migraine during pregnancy and lactation while minimizing the risk for harm to the fetus.
Increased risk for several neonatal, postnatal outcomes for offspring exposed to maternal migraine